Compare IDEXX Laboratories, Inc. (IDXX) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Teradyne, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Teradyne, Inc. trades at $402.19 (market cap $59.34B). The key difference: Teradyne, Inc. is the larger of the two by market cap, and Teradyne, Inc. pays a 0.14% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | TER | |
|---|---|---|
Market Cap | $46.22B | $59.34B |
Sector | Health | Technology |
52-Week High | $766.68 | $483.84 |
52-Week Low | $526.44 | $109.30 |
Enterprise Value | $47.12B | $59.09B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Teradyne (TER) is trading at $402.65, up 10.28% with strong bullish momentum following better-than-expected Q2 2026 earnings. The stock shows robust fundamentals with record revenue of $1.3 billion in Q2, net income margin of 25.77%, and consistent earnings beats. Technical indicators suggest bullish momentum with the current price near resistance at $400, while analyst consensus remains strongly positive with a $481.63 price target.
Outlook remains positive driven by AI-led semiconductor test demand and robotics growth, though elevated valuation multiples (P/E 52.14) and market volatility present risks. The company's strong guidance and institutional support suggest continued upside potential, but investors should monitor competitive pressures in the semiconductor equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
